Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 19 (1), 567

Long Term Response on Regorafenib in non-V600E BRAF Mutated Colon Cancer: A Case Report

Case Reports

Long Term Response on Regorafenib in non-V600E BRAF Mutated Colon Cancer: A Case Report

Eduard Callebout et al. BMC Cancer.


Background: Non-V600E BRAF mutated colorectal cancer (CRC) is a rare disease entity with specific clinical features. These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation. Notably, median overall survival is longer than in wild-type BRAF CRC. Little is known about treatment possibilities in these patients.

Case presentation: We present the case of a 59 year old patient with a rare mutation in BRAF codon 594, who progressed rapidly on all classical therapies but experienced a clear and long lasting response on treatment with Regorafenib.

Conclusion: Little is known about therapies that can be effective in the rare non-V600E BRAF mutated CRCs. We present a patient who had a definite response to treatment with Regorafenib. There are no predictive markers that define a subset of CRC patients who benefit most from Regorafenib. The specific features of this non-V600E BRAF mutated CRC may be relevant in the exploration of predictive biomarkers for the efficacy of Regorafenib.

Keywords: Case report; Colon cancer; Epithelial to mesenchymal transition; Non-V600E BRAF mutation; Regorafenib.

Conflict of interest statement

The authors declare that they have no competing interests.


Fig. 1
Fig. 1
Evolution of periampullary adenopathies on reintroduction of regorafenib. A In january 2017 periampullary adenopathies were seen on follow-up CT-scan. B CT-scan after 6 months of treatment with regorafenib shows a partial response
Fig. 2
Fig. 2
Timeline 2014–2018: Disease characteristics, disease evolution (left column) and therapeutic interventions (right column)

Similar articles

See all similar articles

Cited by 1 article


    1. Ascierto PA, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85. - PMC - PubMed
    1. Sanz-Garcia E, et al. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. Ann Oncol. 2017;28(11):2648–2657. doi: 10.1093/annonc/mdx401. - DOI - PubMed
    1. Cremolini C, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015;26(10):2092–2097. doi: 10.1093/annonc/mdv290. - DOI - PubMed
    1. Jones JC, et al. (Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal Cancer. J Clin Oncol. 2017;35(23):2624. doi: 10.1200/JCO.2016.71.4394. - DOI - PMC - PubMed
    1. Shinozaki E, et al. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the biomarker research for anti-EGFR monoclonal antibodies by comprehensive Cancer genomics (BREAC) study. Br J Cancer. 2017;117(10):1450–1458. doi: 10.1038/bjc.2017.308. - DOI - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts